GALMED PHARMACEUTICALS LTD

GLMDNASDAQ

🏆 #5194 by market capEarnings Nov 24US Equity

$4.59▲ $0.68 (+14.91%)

After hours · at close

🔔

Track GLMD

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 14.9%

7d▲ 0.0%

14d▲ 0.0%

30d▲ 10.1%

ytd▼ 24.7%

1y▼ 59.4%

🏦Market Cap

$5M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $4.54 – $4.62
52-Week Range: $3.29 – $13.20
Volume: $3.20B
Avg Volume: $3.93B
Shares Outstanding: 1.0M
Next Earnings: Oct 31, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $267,917
P/E Ratio: -0.3
P/S Ratio: 0.0x
EPS (TTM): $-11.91
Dividend Yield: 0.00%
Dilution (1yr): +66.7%

Why Investors Own GLMD

✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
✓Healthy economics — 26% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GALMED PHARMACEUTICALS LTD

GLMD

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$9M▲ +35.6% YoY

Free Cash Flow

−$6M▲ +7.4% YoY

Shares Outstanding

823K▲ +66.7% YoY

Net Cash

$4M▼ −$667K YoY

StockOtter · stockotter.space

About GALMED PHARMACEUTICALS LTD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

🦦